JPMorgan Chase & Co. Reaffirms Overweight Rating for Mirum P

JPMorgan Chase & Co. restated their overweight rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $37.00 target price on the stock. A number of other analysts also recently weighed in on the company. Evercore ISI restated […]

Related Keywords

China , Canada , Patrickj Heron , Robertw Baird , Raymond James , Insider Transactions At Mirum Pharmaceuticals , Mirum Pharmaceuticals Price Performance , Brown Brothers Harriman Co , Tower Research Capital , China Universal Asset Management Co , Mirum Pharmaceuticals , Jpmorgan Chase Co , Life Insurance Co , News Ratings For Mirum Pharmaceuticals Daily , Royal Bank , Cantor Fitzgerald , Mirum Pharmaceuticals Inc , Morgan Stanley , Analyst Recommendations For Mirum Pharmaceuticals , Free Report , Get Free Report , Director Michael , Director Patrick , Universal Asset Management , Research Capital , Mirum Pharmaceuticals Daily , Nasdaq Mirm , Smirm , Medical , Reiterated Rating , Jpmorgan Chase Amp Co ,